Market Place
Sourcing Support
NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC
19 Dec 2023 //
BUSINESSWIRE
Interim Results from a NanOlogy Phase 2 Clinical Trial
10 Oct 2023 //
BUSINESSWIRE
NanOlogy Presents Research at 2023 DDW and ASCO Involving Investigational Drugs
07 Jun 2023 //
BUSINESSWIRE
NanOlogy Granted a US Patent for Investigational Drugs with Immune Inhibitors
07 Mar 2023 //
BUSINESSWIRE
NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX
20 Dec 2022 //
BUSINESSWIRE
NanOlogy concludes subject enrolment in Phase IIa lung cancer trial
14 Nov 2022 //
CLINICALTRIALSARENA
NanOlogy Completes Enrollment in Phase 2a Trial of Intratumoral LSAM-PTX
11 Nov 2022 //
BUSINESSWIRE
NanOlogy Publishes Review Article of Research Supporting LSAM-DTX
03 Oct 2022 //
BUSINESSWIRE
NanOlogy Publishes Review Article of Clinical Research Supporting LSAM-DTX
20 Sep 2022 //
BUSINESSWIRE
NanOlogy Publishes Results from a Phase 1/2 Clinical Trial of Docetaxel
01 Aug 2022 //
BUSINESSWIRE
NanOlogy Publishes Results from PI/II Trial of its Topical Investigational Drug
03 May 2022 //
BUSINESSWIRE
Additional Data of Intracystic NanoPac® Presented at DDW® 2021
09 Jun 2021 //
BUSINESSWIRE
NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel)
28 Dec 2020 //
BUSINESSWIRE
NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel)
28 Dec 2020 //
BUSINESSWIRE
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac®
03 Nov 2020 //
PIPELINEREVIEW
NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac®
03 Nov 2020 //
BUSINESSWIRE
NanOlogy Announces Initiation of a Lung Cancer Trial Following FDA Allowances
09 Jun 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.